Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

CDI Expands MyCell Products Line

Published: Monday, July 15, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
Offers access to human disease models and licensing key genetic engineering patents.

Cellular Dynamics International (CDI) has announced that it has expanded its MyCell® Products line, offering access to a number of human disease models and licensing key genetic engineering patents from Life Technologies and Sigma-Aldrich.

CDI’s MyCell Products include custom cell products manufactured using induced pluripotent stem cell (iPSC) technology to make stem cells or differentiated cells from any individual, including those with diseases of interest to pharmaceutical and academic researchers.

CDI’s MyCell Products now offer access to a number of disease models, including cardiomyopathies and arrhythmias, vision disorders, neurological disorders, and muscular dystrophies.

In addition, the company is actively working on expanding its disease model offering, currently working on additional disease models for neurodegenerative disorders and drug-induced liver injury (DILI).

Within the MyCell Products line, CDI maintains the iPSC line of each of the disease models, enabling customers to request manufacture of differentiated cells, such as cardiomyocytes, neurons, hepatocytes, and endothelial cells, for their discovery research.

In addition, CDI has licensed Life Technologies’ GeneArt® Precision TALs (TALENs) and Sigma’s CompoZr® ZFN technologies, which act like genomic scissors to cut DNA in a precise location.

These nuclease technologies facilitate efficient genomic editing by creating double-stranded breaks in DNA at user-specified locations, stimulating the cell’s natural repair process and enabling targeted gene insertions, deletions, or modifications.

CDI will use the TALENs and ZFN technologies to perform genetic engineering specified by the customer, for example to introduce or correct a specific mutation, thus creating human disease models and isogenic controls.

“This expansion of the MyCell Products line is the next step in our growing disease-in-a-dish portfolio and allows our customers more ready access to diseases of interest from our growing catalog of iPSCs,” said Chris Parker, CDI chief commercial officer.

Parker continued, “Through the MyCell Products line, researchers can now access human disease models either through creation of iPSC-derived cells directly from a patient, or through inducing a disease state via use of these TALENs or ZFN technologies.”

Bob Palay, CDI chief executive officer, said, “CDI’s commercial goal has been to provide access to human cells that reproduce human biology, and we see both of these developments as steps toward achieving that goal. We’re pleased to license these nuclease technologies from Life Technologies and Sigma-Aldrich, and the combination of these nuclease technologies with CDI’s iPSC-derived cells creates a new, powerful tool to better understand and target human disease.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SeouLin Bioscience to Distribute Cellular Dynamics' Products in Korea
SeouLin Bioscience will distribute CDI’s iCell® catalog of products.
Friday, August 21, 2015
Cellular Dynamics to Host Annual iForum™ Meetings
Meetings focused on human iPSC research and applications.
Friday, August 14, 2015
Cord Blood Registry and CDI Announce Collaboration
Collaboration to reprogram newborn stem cells into induced pluripotent stem cells.
Wednesday, January 14, 2015
Using iPSC-derived Cells to Coat Blood Vessels in Kidney Scaffolds
Cellular Dynamics and Northwestern University take first steps toward rebuilding an organ using manufactured human cells.
Tuesday, November 18, 2014
Cellular Dynamics International Reports Third Quarter 2014 Financial Results
Cellular Dynamics International, Inc. reported financial results for the third quarter and nine months ended September 30, 2014.
Tuesday, November 11, 2014
Cellular Dynamics Awarded $1.2 M NEI Contract
Contract will see company develop patient-derived stem cells in gear-up for age-related macular degeneration trial.
Tuesday, October 28, 2014
Cellular Dynamics Awarded NEI Contract
Contract awarded for the development of patient-derived stem cells in gear-up for age-related macular degeneration trial.
Monday, October 27, 2014
Cellular Dynamics Awarded U.S. Patent
Patent strengthens CDI’s position as leading manufacturer of human cells for research and clinical applications.
Friday, August 29, 2014
Cellular Dynamics Awarded Pluripotent Stem Cells Patents
Patents secure CDI’s position as leading manufacturer of human cells from most common, easily accessible donor source for research, drug discovery and regenerative medicine.
Thursday, July 10, 2014
Cellular Dynamics Q4 Revenues Increase 41%
Cellular Dynamics International, Inc. reported financial results for the fourth quarter and for the fiscal year ended December 31, 2013.
Tuesday, March 11, 2014
Cellular Dynamics Signs Agreement with Nestlé Institute of Health Sciences
Agreement will see company to supply iCell® and MyCell® products for nutritional research.
Wednesday, January 08, 2014
The Hamner Institutes and Cellular Dynamics Collaborate
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.
Monday, December 09, 2013
Jain Foundation Signs Agreement with Cellular Dynamics
Company will create iPSC lines from patients with muscular dystrophies for use as disease models for basic research and drug discovery.
Wednesday, December 04, 2013
CDI Reports Third Quarter 2013 Financial Results
Revenues more than double.
Wednesday, November 13, 2013
Cellular Dynamics Receives Formal Notice of Grant Award (NGA) for $16 Million Stem Cell Banking Project
NGA signifies entry into a definitive agreement and initiation of funding.
Tuesday, November 05, 2013
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos